Contract Win

IXICO plc

23 May 2024

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

23 May 2024

IXICO plc

("IXICO" or the "Company")

Alzheimer's Disease (AD) trial contract win.

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience announces that it has signed a contract with the Global Alzheimer's Platform Foundation® ("GAP") to support GAP's planned Bio-Hermes 2 trial. The contract value is worth over £1 million over a 48-month term. The Company does not expect to adjust its expectations of performance for the financial year ending 30 September 2024 ("FY24") following the receipt of this contract.

In the Bio-Hermes 2 trial, IXICO will apply its expertise to qualify approximately 30 participating imaging centres for the collection of amyloid PET and tau PET molecular imaging and MR Imaging scans from approximately 1,200 volunteers over the age of 60. The volunteers will be screened for Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD, with IXICO providing both visual read and AI driven quantitative analysis across all three imaging modalities used in the Bio-Hermes 2 trial.

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"We are delighted to deepen our long-term strategic partnership with GAP by building on the success of the initial Bio-Hermes trial to now also be selected to deliver all of the imaging analysis requirements of the Bio-Hermes 2 trial across both MRI and PET. With the significant unmet medical need for new therapies in Alzheimer's Disease, we are excited about the prospects of deepening our collaboration with GAP in support of the success of the Bio-Hermes 2 trial."

John Dwyer, President of Global Alzheimer's Platform Foundation (GAP), commented:

"Our collaboration with IXICO for neuroimaging and AI driven quantitative analysis is a fundamental element of GAP's innovative Bio-Hermes 2 trial, which is taking a novel approach to incorporate a broad set of digital and blood biomarker results for comparison across cognitively normal and impaired individuals. We've also committed to an unprecedented level of participation by traditionally underrepresented populations in AD studies so that the insights generated by BH2 will benefit everyone impacted by Alzheimer's and related dementias."

For further information please contact:

IXICO plc		[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)		[phone]
Giles Balleny / Dan Hodkinson (Corporate Finance) Michael F Johnson / Tamar Cranford Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

 

END